Microneedles for painless transdermal immunotherapeutic applications

Show full item record



Permalink

http://hdl.handle.net/10138/330254

Citation

Amani , H , Shahbazi , M-A , D'Amico , C , Fontana , F , Abbaszadeh , S & Santos , H A 2021 , ' Microneedles for painless transdermal immunotherapeutic applications ' , Journal of Controlled Release , vol. 330 , pp. 185-217 . https://doi.org/10.1016/j.jconrel.2020.12.019

Title: Microneedles for painless transdermal immunotherapeutic applications
Author: Amani, Hamed; Shahbazi, Mohammad-Ali; D'Amico, Carmine; Fontana, Flavia; Abbaszadeh, Samin; Santos, Hélder A.
Contributor: University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Division of Pharmaceutical Chemistry and Technology
University of Helsinki, Nanomedicines and Biomedical Engineering
University of Helsinki, Helsinki One Health (HOH)
Date: 2021-02-10
Language: eng
Number of pages: 33
Belongs to series: Journal of Controlled Release
ISSN: 1873-4995
URI: http://hdl.handle.net/10138/330254
Abstract: Immunotherapy has recently garnered plenty of attention to improve the clinical outcomes in the treatment of various diseases. However, owing to the dynamic nature of the immune system, this approach has often been challenged by concerns regarding the lack of adequate long-term responses in patients. The development of microneedles (MNs) has resulted in the improvement and expansion of immuno-reprogramming strategies due to the housing of high accumulation of dendritic cells, macrophages, lymphocytes, and mast cells in the dermis layer of the skin. In addition, MNs possess many outstanding properties, such as the ability for the painless traverse of the stratum corneum, minimal invasiveness, facile fabrication, excellent biocompatibility, convenient administration, and bypassing the first pass metabolism that allows direct translocation of therapeutics into the systematic circulation. These advantages make MNs excellent candidates for the delivery of immunological biomolecules to the dermal antigen-presenting cells in the skin with the aim of vaccinating or treating different diseases, such as cancer and autoimmune disorders, with minimal invasiveness and side effects. This review discusses the recent advances in engineered MNs and tackles limitations relevant to traditional immunotherapy of various hard-to-treat diseases.
Subject: Allergy
Autoimmune disease
Cancer therapy
Infection
Microneedles
Vaccination
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Microneedles_fo ... erapeutic_applications.pdf 5.176Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record